(Q37104870)

18 August 2017

1 reference

title

Advances in the management of hyperlipidemia-induced atherosclerosis (English)

1 reference

18 August 2017

1 reference

1 reference

Lisa R Tannock

1

1 reference

18 August 2017

1 March 2008

1 reference

Expert Review of Cardiovascular Therapy

18 August 2017

1 reference

18 August 2017

6

1 reference

18 August 2017

3

1 reference

18 August 2017

369-383

1 reference

Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the 1984 coronary primary prevention trial ends it--almost

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

The UMD-LDLR database: additions to the software and 490 new entries to the database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Familial lipoprotein disorders in patients with premature coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Cholesterol reduction yields clinical benefits: meta-analysis including recent trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

CETP inhibitors to increase HDL cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Management of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Risks associated with statin therapy: a systematic overview of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Experience with statin use in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Statin safety: an overview and assessment of the data--2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

The role of coenzyme Q10 in statin-associated myopathy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

An assessment of statin safety by nephrologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Safety considerations with gastrointestinally active lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Effects of Nicotinic Acid Therapy on Plasma High Density Lipoprotein Subfraction Distribution and Composition and on Apolipoprotein A Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Molecular identification of nicotinic acid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Molecular identification of high and low affinity receptors for nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Safety considerations with niacin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Safety considerations with fibrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Angiotensin-converting enzyme inhibitors and coronary heart disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.369

21 January 2018

Identifiers

DOI

10.1586/14779072.6.3.369

1 reference

18 August 2017

1 reference

PubMed ID

18327996